What To Know About COVID-19 And Its Impact On Patients With Psoriasis
Abstract
Coronavirus disease 2019 (COVID-19) is an acute systemic illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel coronavirus was first identified in Wuhan, China in late 2019 and has since had a major impact on global health after being declared a pandemic in the spring of 2020 by the World Health Organization. To date, there have been over 180 million confirmed infections and over 4 million deaths worldwide across multiple ‘waves’.
COVID-19 has had a major impact on dermatology practice in Canada with a shift towards virtual care and a reluctance to prescribe some immunosuppressive medications. However, since those early days, there has been growing comfort with continuing such medications in most cases.
The primary objective of this article is to review the impact of both COVID-19 and COVID-19 vaccination on patients with psoriasis who are taking oral agents and biologics (anti-tumour necrosis factor (TNF), anti-interleukin (IL)-17 and anti-interleukin (IL)-23 inhibitors).
References
John Hopkins. Coronavirus Resource Centre. July 15, 2021. Accessed 2021 July 15 from https://coronavirus.jhu.edu/map.html
Leis M, Fleming P, Lynde CW. Impacts of COVID-19 on Dermatologic Practice, Disease Presentation, and Immunomodulator Prescriptions. Journal of Cutaneous Medicine and Surgery. 2021;25(1):106-108.
Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol. 2008;159(Suppl2):2–9.
Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020;80(6):656-665.
Yousaf A, Gayam S, Feldman S, Zinn Z, Kolodney M. Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: a multicenter research network study. J Am Acad Dermatol. 2021;84:70–75.
Gisondi P, Piaserico S, Naldi L, et al. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience. J Allergy Clin Immunol. 2021;147(2):558-560.e1.
Gelfand JM, Armstrong AW, Bell S, et al. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021 May;84(5):1254-1268.
Skowronski DM, De Serres G. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2021 Apr 22;384(16):1576-1577.
Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021 Apr 15;384(15):1412-1423.
Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416.
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111.
Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021 Jun 10;384(23):2187-2201.
An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): Recommendations on the use of COVID-19 Vaccines. 2021 July 2.
Wong SY, Dixon R, Martinez Pazos V, et al. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology. 2021 Apr 20;S0016-5085(21)00648-X.
Haberman RH, Herati R, Simon D, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease Annals of the Rheumatic Diseases Published Online First. 2021 May 25.
Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. Arthritis Rheumatol. 2021;73(7):1093- 1107.
Krajewski PK, Matusiak Ł, Szepietowski JC. Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine. J Eur Acad Dermatol Venereol. 2021 Jun 16.
McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol. 2021 July;85(1):46-55.
